Wednesday, October 15, 2025

The Daily Chronicle

Bringing you the world's news since 1892

Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611

Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611

PARIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology welcomes the publication of new data reinforcing interest in transferrin (Tf) as a drug candidate for the treatment of dry age-related macular degeneration (AMD), in a study performed by scientists from Inserm and Cochin Hospital in Paris, in collaboration with PulseSight’s scientists.

Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology
Vasa Therapeutics Receives FDA IND Clearance to Advance Novel Small Molecule VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
I’m a spine surgeon — this is absolutely the worst thing you can do for your neck and back
Mississippi hospital recognized nationally and other health care news
Pa. senators push bill mandating cellphone-free school days
The No. 1 Healthiest Breakfast to Eat, According to Doctors
Amazon Pharmacy to launch prescription kiosks at One Medical clinics
American Society of Anesthesiologists Launches First-of-Its-Kind Collaboration with C8 Health
'The gem and the tiara' of Dartmouth Hitchcock Medical Center turns 60
At summit, Mayo Clinic CEO talks AI, campus expansion and retaining staff
Don’t Eat These Hello Fresh Meals, Officials Warn